Cargando…

A review on primary progressive aphasia

Primary progressive aphasia (PPA) is a neurodegenerative disease of insidious onset presenting with progressive isolated loss of language function, without significant impairment in other cognitive domains. Current diagnostic criteria require the language dysfunction to remain isolated for at least...

Descripción completa

Detalles Bibliográficos
Autores principales: Léger, Gabriel C, Johnson, Nancy
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656316/
https://www.ncbi.nlm.nih.gov/pubmed/19300609
_version_ 1782165494228320256
author Léger, Gabriel C
Johnson, Nancy
author_facet Léger, Gabriel C
Johnson, Nancy
author_sort Léger, Gabriel C
collection PubMed
description Primary progressive aphasia (PPA) is a neurodegenerative disease of insidious onset presenting with progressive isolated loss of language function, without significant impairment in other cognitive domains. Current diagnostic criteria require the language dysfunction to remain isolated for at least two years, and to remain the salient feature as the disease progresses, usually to involve other domains such as behavior, executive functions, and judgment. Although PPA in its early stages can usually be differentiated from probable Alzheimer’s disease (PRAD) and the behavioral variant of frontotemporal lobar degeneration by the absence of significant changes in memory and behavior, and the preservation of activities daily living, progression of the disease often leads to deficits more consistent with the latter. Underlying etiologies remain heterogeneous: the neuropathological characteristics associated with frontotemporal lobar degeneration, cortocobasal degeneration, and motor neuron disease are usually found. There is a strong genetic susceptibility with affliction of first-degree relatives with similar disease in up to 40 to 50% in some series. Pathogenic mutations in genes coding for the proteins tau and progranulin have been isolated. These are leading to a better understanding of the neuropathological mechanisms and hopefully targeted disease-modifying therapy. Current therapy is limited to improving mood symptoms and targeting behavior changes as they develop. Referral to specialized centers where speech therapy, counseling, and education for both patient and caregiver are available may be helpful.
format Text
id pubmed-2656316
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26563162009-03-19 A review on primary progressive aphasia Léger, Gabriel C Johnson, Nancy Neuropsychiatr Dis Treat Review Primary progressive aphasia (PPA) is a neurodegenerative disease of insidious onset presenting with progressive isolated loss of language function, without significant impairment in other cognitive domains. Current diagnostic criteria require the language dysfunction to remain isolated for at least two years, and to remain the salient feature as the disease progresses, usually to involve other domains such as behavior, executive functions, and judgment. Although PPA in its early stages can usually be differentiated from probable Alzheimer’s disease (PRAD) and the behavioral variant of frontotemporal lobar degeneration by the absence of significant changes in memory and behavior, and the preservation of activities daily living, progression of the disease often leads to deficits more consistent with the latter. Underlying etiologies remain heterogeneous: the neuropathological characteristics associated with frontotemporal lobar degeneration, cortocobasal degeneration, and motor neuron disease are usually found. There is a strong genetic susceptibility with affliction of first-degree relatives with similar disease in up to 40 to 50% in some series. Pathogenic mutations in genes coding for the proteins tau and progranulin have been isolated. These are leading to a better understanding of the neuropathological mechanisms and hopefully targeted disease-modifying therapy. Current therapy is limited to improving mood symptoms and targeting behavior changes as they develop. Referral to specialized centers where speech therapy, counseling, and education for both patient and caregiver are available may be helpful. Dove Medical Press 2007-12 /pmc/articles/PMC2656316/ /pubmed/19300609 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Léger, Gabriel C
Johnson, Nancy
A review on primary progressive aphasia
title A review on primary progressive aphasia
title_full A review on primary progressive aphasia
title_fullStr A review on primary progressive aphasia
title_full_unstemmed A review on primary progressive aphasia
title_short A review on primary progressive aphasia
title_sort review on primary progressive aphasia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656316/
https://www.ncbi.nlm.nih.gov/pubmed/19300609
work_keys_str_mv AT legergabrielc areviewonprimaryprogressiveaphasia
AT johnsonnancy areviewonprimaryprogressiveaphasia
AT legergabrielc reviewonprimaryprogressiveaphasia
AT johnsonnancy reviewonprimaryprogressiveaphasia